Assembly Biosciences (ASMB)

Feb 26, 2025, 8:00 AM EST - 10 days ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 16 days ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 2 months ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Jul 15, 2024, 8:00 AM EDT - 8 months ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 9 months ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 10 months ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 10 months ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Feb 8, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Nov 10, 2023, 4:05 PM EST - 1 year ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 1 year ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Oct 17, 2023, 7:00 AM EDT - 1 year ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 1 year ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Jul 17, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 1 year ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Jan 17, 2023, 7:00 AM EST - 2 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Nov 4, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Oct 24, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 5, 2022, 4:05 PM EDT - 2 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Aug 9, 2022, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 20, 2022, 4:05 PM EDT - 2 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jun 22, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 8, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 6, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

May 12, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Mar 10, 2022, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Feb 9, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Jan 7, 2022, 5:00 PM EST - 3 years ago

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

Nov 12, 2021, 8:00 AM EST - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

Nov 1, 2021, 10:32 AM EDT - 3 years ago

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

Oct 19, 2021, 7:30 AM EDT - 3 years ago

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Oct 6, 2021, 8:00 AM EDT - 3 years ago

Assembly Bio Announces October Conference Participation

Sep 1, 2021, 4:02 PM EDT - 3 years ago

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

Aug 18, 2021, 8:00 AM EDT - 3 years ago

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

Aug 5, 2021, 4:01 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Aug 3, 2021, 8:00 AM EDT - 3 years ago

Assembly Bio Announces Key Promotions to Leadership Team

Jul 20, 2021, 8:00 AM EDT - 3 years ago

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

Jun 9, 2021, 8:00 AM EDT - 4 years ago

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

Mar 19, 2021, 12:20 PM EDT - 4 years ago

3 Net Current Asset Value Stocks

LUMO UTSI

Feb 28, 2021, 4:57 PM EST - 4 years ago

Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript

Feb 26, 2021, 11:52 AM EST - 4 years ago

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

ABUS

Feb 26, 2021, 6:41 AM EST - 4 years ago

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy